The Public Accounts Committee of the House of Representatives has queried the National Institute for Pharmaceutical Research and Development over the diversion of its N4 billion COVID-19 intervention fund.
At its resumed probe into COVID-19 expenditure by government agencies, the committee accused the Institute of flouting the law.
A three-man team from the National Institute for Pharmaceutical Research and Development, led by its Director General, Peter Adigwe, appears before the Committee on the utilisation of the N4 billion COVID-19 intervention fund.
Mr. Adigwe admitted he led the research team during the COVID-19 pandemic.
He said N2 billion each was allotted for recurrent expenditure and capital projects, but more money was spent on capital items.
Peter Adigwe tells the lawmakers that majority of the funds allocated to capital expenditure went into equipping 15 laboratories in NIPRD and building a 5-storey facility.
But the legislators picked holes in many of the line items submitted by the Institute.
They disagreed with the Director General over comments that the Institute diverted the COVID-19 fund for other purposes, particularly because it was not being funded.
The Committee says it uncovered varying discrepancies and directed the Institute to tidy up its documents for another appearance.
It also summoned three Contracting firms awarded the supply of equipment.
The Public Accounts Committee of the House of Representatives has queried the National Institute for Pharmaceutical Research and Development over the diversion of its N4 billion COVID-19 intervention fund.
At its resumed probe into COVID-19 expenditure by government agencies, the committee accused the Institute of flouting the law.
A three-man team from the National Institute for Pharmaceutical Research and Development, led by its Director General, Peter Adigwe, appears before the Committee on the utilisation of the N4 billion COVID-19 intervention fund.
Mr. Adigwe admitted he led the research team during the COVID-19 pandemic.
He said N2 billion each was allotted for recurrent expenditure and capital projects, but more money was spent on capital items.
Peter Adigwe tells the lawmakers that majority of the funds allocated to capital expenditure went into equipping 15 laboratories in NIPRD and building a 5-storey facility.
But the legislators picked holes in many of the line items submitted by the Institute.
They disagreed with the Director General over comments that the Institute diverted the COVID-19 fund for other purposes, particularly because it was not being funded.
The Committee says it uncovered varying discrepancies and directed the Institute to tidy up its documents for another appearance.
It also summoned three Contracting firms awarded the supply of equipment.
The Public Accounts Committee of the House of Representatives has queried the National Institute for Pharmaceutical Research and Development over the diversion of its N4 billion COVID-19 intervention fund.
At its resumed probe into COVID-19 expenditure by government agencies, the committee accused the Institute of flouting the law.
A three-man team from the National Institute for Pharmaceutical Research and Development, led by its Director General, Peter Adigwe, appears before the Committee on the utilisation of the N4 billion COVID-19 intervention fund.
Mr. Adigwe admitted he led the research team during the COVID-19 pandemic.
He said N2 billion each was allotted for recurrent expenditure and capital projects, but more money was spent on capital items.
Peter Adigwe tells the lawmakers that majority of the funds allocated to capital expenditure went into equipping 15 laboratories in NIPRD and building a 5-storey facility.
But the legislators picked holes in many of the line items submitted by the Institute.
They disagreed with the Director General over comments that the Institute diverted the COVID-19 fund for other purposes, particularly because it was not being funded.
The Committee says it uncovered varying discrepancies and directed the Institute to tidy up its documents for another appearance.
It also summoned three Contracting firms awarded the supply of equipment.
The Public Accounts Committee of the House of Representatives has queried the National Institute for Pharmaceutical Research and Development over the diversion of its N4 billion COVID-19 intervention fund.
At its resumed probe into COVID-19 expenditure by government agencies, the committee accused the Institute of flouting the law.
A three-man team from the National Institute for Pharmaceutical Research and Development, led by its Director General, Peter Adigwe, appears before the Committee on the utilisation of the N4 billion COVID-19 intervention fund.
Mr. Adigwe admitted he led the research team during the COVID-19 pandemic.
He said N2 billion each was allotted for recurrent expenditure and capital projects, but more money was spent on capital items.
Peter Adigwe tells the lawmakers that majority of the funds allocated to capital expenditure went into equipping 15 laboratories in NIPRD and building a 5-storey facility.
But the legislators picked holes in many of the line items submitted by the Institute.
They disagreed with the Director General over comments that the Institute diverted the COVID-19 fund for other purposes, particularly because it was not being funded.
The Committee says it uncovered varying discrepancies and directed the Institute to tidy up its documents for another appearance.
It also summoned three Contracting firms awarded the supply of equipment.
The Public Accounts Committee of the House of Representatives has queried the National Institute for Pharmaceutical Research and Development over the diversion of its N4 billion COVID-19 intervention fund.
At its resumed probe into COVID-19 expenditure by government agencies, the committee accused the Institute of flouting the law.
A three-man team from the National Institute for Pharmaceutical Research and Development, led by its Director General, Peter Adigwe, appears before the Committee on the utilisation of the N4 billion COVID-19 intervention fund.
Mr. Adigwe admitted he led the research team during the COVID-19 pandemic.
He said N2 billion each was allotted for recurrent expenditure and capital projects, but more money was spent on capital items.
Peter Adigwe tells the lawmakers that majority of the funds allocated to capital expenditure went into equipping 15 laboratories in NIPRD and building a 5-storey facility.
But the legislators picked holes in many of the line items submitted by the Institute.
They disagreed with the Director General over comments that the Institute diverted the COVID-19 fund for other purposes, particularly because it was not being funded.
The Committee says it uncovered varying discrepancies and directed the Institute to tidy up its documents for another appearance.
It also summoned three Contracting firms awarded the supply of equipment.
The Public Accounts Committee of the House of Representatives has queried the National Institute for Pharmaceutical Research and Development over the diversion of its N4 billion COVID-19 intervention fund.
At its resumed probe into COVID-19 expenditure by government agencies, the committee accused the Institute of flouting the law.
A three-man team from the National Institute for Pharmaceutical Research and Development, led by its Director General, Peter Adigwe, appears before the Committee on the utilisation of the N4 billion COVID-19 intervention fund.
Mr. Adigwe admitted he led the research team during the COVID-19 pandemic.
He said N2 billion each was allotted for recurrent expenditure and capital projects, but more money was spent on capital items.
Peter Adigwe tells the lawmakers that majority of the funds allocated to capital expenditure went into equipping 15 laboratories in NIPRD and building a 5-storey facility.
But the legislators picked holes in many of the line items submitted by the Institute.
They disagreed with the Director General over comments that the Institute diverted the COVID-19 fund for other purposes, particularly because it was not being funded.
The Committee says it uncovered varying discrepancies and directed the Institute to tidy up its documents for another appearance.
It also summoned three Contracting firms awarded the supply of equipment.
The Public Accounts Committee of the House of Representatives has queried the National Institute for Pharmaceutical Research and Development over the diversion of its N4 billion COVID-19 intervention fund.
At its resumed probe into COVID-19 expenditure by government agencies, the committee accused the Institute of flouting the law.
A three-man team from the National Institute for Pharmaceutical Research and Development, led by its Director General, Peter Adigwe, appears before the Committee on the utilisation of the N4 billion COVID-19 intervention fund.
Mr. Adigwe admitted he led the research team during the COVID-19 pandemic.
He said N2 billion each was allotted for recurrent expenditure and capital projects, but more money was spent on capital items.
Peter Adigwe tells the lawmakers that majority of the funds allocated to capital expenditure went into equipping 15 laboratories in NIPRD and building a 5-storey facility.
But the legislators picked holes in many of the line items submitted by the Institute.
They disagreed with the Director General over comments that the Institute diverted the COVID-19 fund for other purposes, particularly because it was not being funded.
The Committee says it uncovered varying discrepancies and directed the Institute to tidy up its documents for another appearance.
It also summoned three Contracting firms awarded the supply of equipment.
The Public Accounts Committee of the House of Representatives has queried the National Institute for Pharmaceutical Research and Development over the diversion of its N4 billion COVID-19 intervention fund.
At its resumed probe into COVID-19 expenditure by government agencies, the committee accused the Institute of flouting the law.
A three-man team from the National Institute for Pharmaceutical Research and Development, led by its Director General, Peter Adigwe, appears before the Committee on the utilisation of the N4 billion COVID-19 intervention fund.
Mr. Adigwe admitted he led the research team during the COVID-19 pandemic.
He said N2 billion each was allotted for recurrent expenditure and capital projects, but more money was spent on capital items.
Peter Adigwe tells the lawmakers that majority of the funds allocated to capital expenditure went into equipping 15 laboratories in NIPRD and building a 5-storey facility.
But the legislators picked holes in many of the line items submitted by the Institute.
They disagreed with the Director General over comments that the Institute diverted the COVID-19 fund for other purposes, particularly because it was not being funded.
The Committee says it uncovered varying discrepancies and directed the Institute to tidy up its documents for another appearance.
It also summoned three Contracting firms awarded the supply of equipment.
Related posts:
House of Reps to probe Reps funds for rehabilitation, maintenance of Refineries
House of Reps moves to stop implementation of Bama Initiative funds
House of Reps wants more funds allocated to Judiciary
Nasarawa State Backs House Of Reps TETFUND Investigation
Abraka building collapse:Developer, contractor arrested as investigation continues
Former Barcelona President, Bartomeu, Others arrested as investigation of club continues
House Charges FG On Roads, To Probe Covid-19 Funds Use
Reps give fed. ministry of health 7 days to return N10bn covid-19 funds to federation account
